Aptevo Therapeutics Incis A Clinical Stage Biotechnology Company Based In Seattlewashingtonthe Company Focuses On Developing Innovative Immunotherapies For Cancer Treatment Using Its Proprietary Adaptir And Adaptir Flex Platform Technologiesthese Platforms Facilitate The Creation Of Various Immunotherapeutic Proteins Aimed At Enhancing Immune Responses Against Cancer Cells Aptevo S Pipeline Includes Both Clinical And Preclinical Candidatesclinical Candidates Include Mipletamig For Acute Myeloid Leukemia And Alg Apv 527Which Targets Specific Antigens In Solid Tumorsthe Preclinical Candidates Feature Apvo603A Dual Agonist For 4 1Bb And Ox40Apvo442 For Prostate Cancerand Apvo711Which Stimulates Cd40 While Inhibiting The Pd 1 Pd L1 Pathwaythe Company Is Dedicated To Improving Treatment Outcomes And The Lives Of Cancer Patients Through Its Advancements In Immuno Oncology
